In Vivo Pharmacodynamic Evaluation of STZ Induced Diabetic Model (CAT#: STEM-AE-0663-LGZ)

Streptozotocin (STZ) is an antibiotic that produces pancreatic islet β-cell destruction and is widely used experimentally to produce a model of type 1 diabetes mellitus (T1DM). STZ is a nitroso-containing compound that can specifically destroy islet B cells and increase the oxidative invasion of islet B cells by inducing the synthesis of nitric oxide (NO). It is generally believed that low-dose multiple injections of STZ can induce type 1 diabetes in experimental animals. The mechanism may be that after injection of low-dose STZ, a small number of islet cells are destroyed, and the dead islet cells release sensitizing proteins as antigens by macrophages. Phagocytosis, producing Th1-stimulating factor (IL-12), and inducing increased secretion of IL-2 and IFN-γ, forming inflammatory cell infiltration in the local islet, releasing cytokines such as IL-1β, TNF-α, IFN-γ and oxygen free radicals to kill a small number of cells. Dead cells use themselves as antigens, and after being processed by APC cells, release cytokines, amplify the cell damage effect, and eventually lead to type 1 diabetes.

Metabolic Disease

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

• Sample Type: liquid or powder